Market overview
The global liposome market is worth USD 5.2 bn in 2026 and is forecast to reach USD 11.1 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Anticancer is the largest by drug class segment.
| Scope | Pharmaceutical products delivered in liposomes, lipid vesicles that carry a drug: liposomal doxorubicin, amphotericin B, irinotecan, bupivacaine, vincristine and similar injectables. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 4.8 bn |
| Value 2026 | USD 5.2 bn |
| Value 2036 | USD 11.1 bn |
| CAGR 2026-2036 | 8.0% |
| Volume 2026 | 12.8 million doses |
| Volume 2036 | 26.4 million doses |
| Average price 2026 | USD 402 per dose |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Liposome market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 5.2 bn |
| 2027 | USD 5.6 bn |
| 2028 | USD 6.0 bn |
| 2029 | USD 6.5 bn |
| 2030 | USD 7.0 bn |
| 2031 | USD 7.6 bn |
| 2032 | USD 8.2 bn |
| 2033 | USD 8.8 bn |
| 2034 | USD 9.6 bn |
| 2035 | USD 10.3 bn |
| 2036 | USD 11.1 bn |
Liposome market segmentation
By drug class
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Anticancer | 52.0% | 55.4% | USD 2.7 bn | 8.7% |
| Antifungal | 19.0% | 15.3% | USD 980 mn | 5.7% |
| Pain management | 16.0% | 14.8% | USD 826 mn | 7.2% |
| Other | 13.0% | 14.5% | USD 671 mn | 9.2% |
By route
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Intravenous | 72.0% | 69.4% | USD 3.7 bn | 7.6% |
| Local injection and infiltration | 16.0% | 14.7% | USD 826 mn | 7.1% |
| Inhaled, topical and other | 12.0% | 15.9% | USD 619 mn | 11.1% |
By lipid composition
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Phospholipid liposomes | 44.0% | 41.0% | USD 2.3 bn | 7.2% |
| PEGylated liposomes | 26.0% | 27.0% | USD 1.3 bn | 8.4% |
| Cationic liposomes | 14.0% | 16.0% | USD 722 mn | 9.4% |
| Ligand-targeted liposomes | 16.0% | 16.0% | USD 826 mn | 8.0% |
By application
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 42.0% | 40.0% | USD 2.2 bn | 7.5% |
| Infectious disease | 18.0% | 16.0% | USD 929 mn | 6.7% |
| Vaccines and gene delivery | 14.0% | 20.0% | USD 722 mn | 11.9% |
| Pain management | 12.0% | 11.0% | USD 619 mn | 7.1% |
| Cosmeceutical and nutrition | 14.0% | 13.0% | USD 722 mn | 7.2% |
By development stage
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Marketed products | 62.0% | 55.0% | USD 3.2 bn | 6.7% |
| Clinical stage | 30.0% | 33.0% | USD 1.5 bn | 9.0% |
| Preclinical stage | 8.0% | 12.0% | USD 413 mn | 12.5% |
Top 25 countries for liposome by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.5% of 2026 revenue and the 25 countries below together hold 97.5%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 2.4 bn | 46.0% | USD 5.0 bn | 7.8% |
| 2 | Japan | USD 464 mn | 9.0% | USD 813 mn | 5.8% |
| 3 | China | USD 361 mn | 7.0% | USD 1.1 bn | 12.2% |
| 4 | Germany | USD 310 mn | 6.0% | USD 657 mn | 7.8% |
| 5 | France | USD 258 mn | 5.0% | USD 524 mn | 7.3% |
| 6 | United Kingdom | USD 206 mn | 4.0% | USD 434 mn | 7.7% |
| 7 | Italy | USD 206 mn | 4.0% | USD 412 mn | 7.2% |
| 8 | Spain | USD 155 mn | 3.0% | USD 312 mn | 7.3% |
| 9 | Canada | USD 155 mn | 3.0% | USD 323 mn | 7.6% |
| 10 | South Korea | USD 129 mn | 2.5% | USD 312 mn | 9.2% |
| 11 | Sweden | USD 73 mn | 1.4% | USD 160 mn | 8.2% |
| 12 | Poland | USD 61 mn | 1.2% | USD 135 mn | 8.2% |
| 13 | Turkey | USD 52 mn | 1.0% | USD 114 mn | 8.2% |
| 14 | Switzerland | USD 43 mn | 0.8% | USD 95 mn | 8.1% |
| 15 | Netherlands | USD 34 mn | 0.7% | USD 75 mn | 8.3% |
| 16 | India | USD 29 mn | 0.6% | USD 65 mn | 8.2% |
| 17 | Australia | USD 24 mn | 0.5% | USD 52 mn | 8.2% |
| 18 | Brazil | USD 19 mn | 0.4% | USD 42 mn | 8.3% |
| 19 | Belgium | USD 16 mn | 0.3% | USD 36 mn | 8.3% |
| 20 | Ireland | USD 14 mn | 0.3% | USD 32 mn | 8.4% |
| 21 | Taiwan | USD 13 mn | 0.2% | USD 28 mn | 8.0% |
| 22 | Israel | USD 11 mn | 0.2% | USD 23 mn | 8.0% |
| 23 | Denmark | USD 8.8 mn | 0.2% | USD 20 mn | 8.6% |
| 24 | Mexico | USD 7.7 mn | 0.1% | USD 17 mn | 8.0% |
| 25 | Austria | USD 6.2 mn | 0.1% | USD 14 mn | 8.9% |
| Rest of world | USD 130 mn | 2.5% | USD 284 mn | 8.1% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Gilead Sciences
- Johnson and Johnson
- Pacira BioSciences
- Jazz Pharmaceuticals
- Baxter
Group 2: Regional and specialist players
- Ipsen
- Sun Pharmaceutical
- Teva
- Fresenius Kabi
- Dr. Reddy's Laboratories
- Zydus Lifesciences
- CSPC Pharmaceutical
- Luye Pharma
- Sumitomo Pharma
Group 3: Emerging and niche players
- Lipoid
- Avanti Polar Lipids
- Taiwan Liposome Company
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the liposome market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.
The market is divided by drug class, by route, by lipid composition, by application, by development stage. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the liposome market?
The global liposome market is estimated at USD 4.8 bn in 2025 and USD 5.2 bn in 2026.
How fast will the liposome market grow?
It is forecast to reach USD 11.1 bn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 6.0 bn.
Which country is the largest market for liposome?
United States is the largest market by revenue at USD 2.4 bn in 2026, 46.0% of the global total. The three largest countries together hold 62.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 12.2% a year from 2026 to 2036.
Which liposome segment is largest?
In the by drug class split, Anticancer is the largest segment with 52.0% of 2026 revenue.
Who are the leading liposome companies?
Global leaders include Gilead Sciences, Johnson and Johnson, Pacira BioSciences, Jazz Pharmaceuticals.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Patient RecruitmentUSD 5.2 bn · 9.0% CAGR
- Sterile Single-Use Endoscopy AccessoriesUSD 5.4 bn · 7.5% CAGR
- Aseptic FillingUSD 4.8 bn · 8.0% CAGR
- Omega-3 SupplementsUSD 5.5 bn · 6.0% CAGR
- Clinical Trial SupplyUSD 5.7 bn · 9.0% CAGR
- Track and TraceUSD 5.7 bn · 9.5% CAGR
- Flow CytometryUSD 5.7 bn · 7.5% CAGR
- Safety SyringeUSD 4.5 bn · 8.0% CAGR